Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-20-011263

Chief R&D Officer sold 4,774 shares at $22.35 ($106,699)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Zalevsky Jonathan Chief R&D Officer 2020-02-18 Sale −4,774 $22.35 $106,699 327,073 D
Open-market sales · 4,774 sh · avg $22.35 · $106,699
Loading xslF345X03/doc4.xml…